{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:48:49Z","timestamp":1792234129011,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jcf.2025.03.002","type":"journal-article","created":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T00:58:12Z","timestamp":1741481892000},"page":"469-475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["CFTR modulators and pregnancy outcomes: Early findings from a nationwide cohort study"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9626-3571","authenticated-orcid":false,"given":"Laurent","family":"Chouchana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2398-0396","authenticated-orcid":false,"given":"Mathis","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2045-4742","authenticated-orcid":false,"given":"Jean-Marc","family":"Treluyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2025.03.002_bib0001","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1471-0528.2002.01511.x","article-title":"French cystic fibrosis registry. cystic fibrosis and pregnancy. report from french data (1980-1999)","volume":"109","author":"Gillet","year":"2002","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"10.1016\/j.jcf.2025.03.002_bib0002","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jcf.2019.06.003","article-title":"Pregnancy outcome in women with cystic fibrosis and poor pulmonary function","volume":"19","author":"Reynaud","year":"2020","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.jcf.2025.03.002_bib0003","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic Fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.03.002_bib0004","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/17476348.2024.2357210","article-title":"Unmet challenges in cystic fibrosis treatment with modulators","volume":"18","author":"Corrao","year":"2024","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jcf.2025.03.002_bib0005","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.clinthera.2023.01.016","article-title":"The impact of highly effective cystic fibrosis transmembrane conductance regulator modulators on the health of female subjects with cystic fibrosis","volume":"45","author":"Taylor-Cousar","year":"2023","journal-title":"Clin Ther"},{"key":"10.1016\/j.jcf.2025.03.002_bib0006","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jcf.2018.10.009","article-title":"Failure to conceive in women with CF is associated with pancreatic insufficiency and advancing age","volume":"18","author":"Shteinberg","year":"2019","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.jcf.2025.03.002_bib0007","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jcf.2020.12.011","article-title":"Elexacafator\/tezacaftor\/ivacaftor resolves subfertility in females with CF: a two center case series","volume":"20","author":"O'Connor","year":"2021","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.jcf.2025.03.002_bib0008","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/ppul.26706","article-title":"Use of CFTR modulators in special populations, part 1: pregnancy and lactation","volume":"58","author":"Elijah","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2025.03.002_bib0009","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.03.002_bib0010","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.03.002_bib0011","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.03.002_bib0012","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.03.002_bib0013","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.jcf.2025.03.002_bib0014","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.03.002_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.therap.2023.01.009","article-title":"Performing pharmacoepidemiological studies using the French health insurance data warehouse (SNDS): how to translate guidelines into practice","author":"de Germay","year":"2023","journal-title":"Therapies"},{"key":"10.1016\/j.jcf.2025.03.002_bib0016","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jcf.2025.03.002_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0295897","article-title":"Trends in harmful drug exposure during pregnancy in France between 2013 and 2019: a nationwide cohort study","volume":"19","author":"Louchet","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.jcf.2025.03.002_bib0018","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/pds.4556","article-title":"Development of an algorithm to identify pregnancy episodes and related outcomes in health care claims databases: an application to antiepileptic drug use in 4.9 million pregnant women in France","volume":"27","author":"Bloti\u00e8re","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jcf.2025.03.002_bib0019","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/jech-2011-200311","article-title":"Construction of an adaptable European transnational ecological deprivation index: the French version","volume":"66","author":"Pornet","year":"2012","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.jcf.2025.03.002_bib0020","unstructured":"European network of population-based registries for the epidemiological surveillance of congenital anomalies (Eurocat). https:\/\/eu-rd-platform.jrc.ec.europa.eu\/eurocat\/data-collection\/guidelines-for-data-registration_en (accessed July 13, 2020)."},{"key":"10.1016\/j.jcf.2025.03.002_bib0021","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/pds.982","article-title":"Assessing teratogenicity of antiretroviral drugs: monitoring and analysis plan of the Antiretroviral Pregnancy Registry","volume":"13","author":"Covington","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jcf.2025.03.002_bib0022","unstructured":"FDA. Summary of product characteristics TRIKAFTA. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212273s000lbl.pdf."},{"key":"10.1016\/j.jcf.2025.03.002_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1265138","article-title":"Ocular development after highly effective modulator treatment early in life","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2025.03.002_bib0025","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jcf.2021.12.004","article-title":"Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor","volume":"21","author":"Collins","year":"2022","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.jcf.2025.03.002_bib0026","article-title":"Fetal drug exposure after maternally administered CFTR modulators Elexacaftor\/Tezacaftor\/Ivacaftor in a rat model","volume":"171","author":"Li","year":"2024","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"key":"10.1016\/j.jcf.2025.03.002_bib0027","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcf.2015.11.013","article-title":"A successful uncomplicated CF pregnancy while remaining on Ivacaftor","volume":"15","author":"Kaminski","year":"2016","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.jcf.2025.03.002_bib0028","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jogn.2016.08.011","article-title":"A case report of pregnancy during use of targeted therapeutics for cystic fibrosis","volume":"46","author":"Ladores","year":"2017","journal-title":"J Obstet Gynecol Neonatal Nurs JOGNN"},{"key":"10.1016\/j.jcf.2025.03.002_bib0029","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jcf.2018.05.009","article-title":"Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding","volume":"17","author":"Trimble","year":"2018","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.jcf.2025.03.002_bib0030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1055\/a-0973-8565","article-title":"Successful pregnancy of a patient with Cystic Fibrosis genotype F508del\/F508del and progressed pulmonary destruction on lumacaftor\/ivacaftor","volume":"231","author":"Mainz","year":"2019","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.jcf.2025.03.002_bib0031","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.jcf.2019.12.004","article-title":"To be or not to be on CFTR modulators during pregnancy: risks to be considered","volume":"19","author":"Vekaria","year":"2020","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.jcf.2025.03.002_bib0032","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.jcf.2025.03.002_bib0033","first-page":"e17427","article-title":"Cystic fibrosis transmembrane conductance regulator modulators during pregnancy: a case series","volume":"13","author":"Kendle","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.jcf.2025.03.002_bib0034","article-title":"Experience to date with CFTR modulators during pregnancy and breastfeeding in the British Columbia Cystic Fibrosis clinic","volume":"40","author":"Goodwin","year":"2022","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jcf.2025.03.002_bib0035","article-title":"Successful pregnancy in a cystic fibrosis patient with a severe impairment of lung function receiving Elexacaftor-Tezacaftor-Ivacaftor","volume":"40","author":"Balmpouzis","year":"2022","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jcf.2025.03.002_bib0036","article-title":"Comparison of two pregnancies with and without elexacaftor-tezacaftor-ivacaftor in a woman with cystic fibrosis","volume":"83","author":"Chamagne","year":"2023","journal-title":"Respir Med Res"},{"key":"10.1016\/j.jcf.2025.03.002_bib0037","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jcf.2020.02.018","article-title":"Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators - an international survey","volume":"19","author":"Nash","year":"2020","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.jcf.2025.03.002_bib0038","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation","volume":"20","author":"Taylor-Cousar","year":"2021","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.jcf.2025.03.002_bib0039","first-page":"4","article-title":"Maternal co-morbidities and neonatal outcomes associated with cystic fibrosis","volume":"30","author":"Jelin","year":"2017","journal-title":"J Matern-Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet"},{"key":"10.1016\/j.jcf.2025.03.002_bib0040","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1111\/1471-0528.16423","article-title":"The outcome of pregnancy in women with cystic fibrosis: a UK population-based descriptive study","volume":"127","author":"Ashcroft","year":"2020","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"10.1016\/j.jcf.2025.03.002_bib0041","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1513\/AnnalsATS.202312-1065OC","article-title":"Multisystemic effects of Elexacaftor\u2013Tezacaftor\u2013Ivacaftor in adults with cystic fibrosis and advanced Lung disease","volume":"21","author":"Burgel","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2025.03.002_bib0042","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/pds.4789","article-title":"Use of real-world evidence from healthcare utilization data to evaluate drug safety during pregnancy","volume":"28","author":"Huybrechts","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325000700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325000700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T20:29:21Z","timestamp":1748982561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325000700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1569199325000700"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.03.002","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CFTR modulators and pregnancy outcomes: Early findings from a nationwide cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}